Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advanced<em>EGFR</em>mutation-positive lung adenocarcinoma

Background and purpose: For patients with advanced lung adenocarcinoma harboring an activating EGFR gene mutation, the current standard of care is EGFR-TKI alone. This study aimed to compare efficacy and safety of gefitinib plus chemotherapy with gefitinib or chemotherapy alone for treating advanced...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	金　波, 张岩巍, 韩宝惠
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Editorial Office of China Oncology 2015-12-01
Schriftenreihe:	Zhongguo aizheng zazhi
Schlagworte:	Lung adenocarcinoma <em>EGFR</em>mutation Chemotherapy Gefitinib
Online-Zugang:	http://www.china-oncology.com/thesisDetails#10.3969/j.issn.1007-3969.2015.10.001
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!